Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-Period, Randomised, Crossover Study Designed to Evaluate the In Vivo Performance of a Modified Release Formulation of Alicaforsen in Healthy Male Subjects in the Fed and Fasted State

NCT03473626 is registered in ClinicalTrials.gov with Atlantic Pharmaceuticals Ltd as lead sponsor.

NCT NCT03473626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03473626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-Period, Randomised, Crossover Study Designed to Evaluate the In Vivo Performance of a Modified Release Formulation of Alicaforsen in Healthy Male Subjects in the Fed and Fasted State
Lead sponsor
Atlantic Pharmaceuticals Ltd
Phase
Phase 1
Overall status
Completed
Start date
March 16, 2018
Completion date
April 6, 2018
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ibd